Annual General Meeting FY 2022/23
Documents for the Annual General Meeting on 12 March 2024:
Item 1: Submission of the adopted separate annual financial statements and of the approved consolidated financial statements of BRAIN Biotech AG for the fiscal year ending 30 September 2023, the separate management report and the Group management report for the fiscal year from 1 October 2022 until 30 September 2023 with the explanatory reports relating to disclosures pursuant to Sections 289a and 315a of the German Commercial Code (HGB), as well as the report by the Supervisory Board for the fiscal year from 1 October 2022 to 30 September 2023
Item 2: Resolution concerning the ratification of the actions of the Management Board for the fiscal year from 1 October 2022 to 30 September 2023
The Management and Supervisory boards propose that the actions of the Management Board members holding office during the fiscal year from 1 October 2022 to 30 September 2023 be ratified for this period.
Item 3: Resolution concerning the ratification of the actions of the Supervisory Board for the fiscal year from 1 October 2022 to 30 September 2023
The Management and Supervisory boards propose that the actions of the Supervisory Board members holding office during the fiscal year from 1 October 2022 to 30 September 2023 be ratified for this period.
Item 4: Election of the auditor of the separate financial statements and of the auditor of the consolidated financial statements for the fiscal year from 1 October 2023 to 30 September 2024
Pursuant to the recommendation of its Audit Committee, the Supervisory Board proposes electing
Baker Tilly GmbH & Co KG Wirtschaftsprüfungsgesellschaft (Düsseldorf)
to be the auditor of the separate and consolidated financial statements for the fiscal year from 1 October 2023 to 30 September 2024.
Item 5: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 2,000,000.0
Item 6: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and Hessen Kapital I GmbH with contributed capital of € 1,500,000.00
Item 7: Resolution to approve the conclusion of an agreement relating to the establishment of a typical silent partnership between BRAIN Biotech AG and MBG H Mittelständische Beteiligungsgesellschaft Hessen mbH with contributed capital of € 1,500,000.00
Item 8: Resolution concerning the approval of the Compensation Report
The Management and Supervisory boards propose that the Compensation Report for the 2022/23 fiscal year, prepared and audited in accordance with Section 162 AktG, be approved.